Protalix BioTherapeutics Inc [PLX] stock is trading at $2.06, up 5.10%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The PLX shares have gain 10.16% over the last week, with a monthly amount glided 28.75%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Protalix BioTherapeutics Inc [AMEX: PLX] stock has seen the most recent analyst activity on June 08, 2020, when H.C. Wainwright reiterated its Buy rating and also boosted its price target to $11 from $3. Previously, Rodman & Renshaw reaffirmed its Buy rating on April 17, 2017, and elevated its price target to $5. On April 04, 2016, Rodman & Renshaw initiated with a Buy rating and assigned a price target of $3.50 on the stock. Jefferies upgraded its rating to a Buy and increased its price target to $2.60 on April 23, 2015. R. F. Lafferty reiterated its recommendation of a Buy and reduced its price target to $5 on November 12, 2014. R. F. Lafferty started tracking with a Buy rating for this stock on January 24, 2014, and assigned it a price target of $8. In a note dated May 02, 2012, Oppenheimer reiterated an Outperform rating on this stock and boosted its target price from $9 to $11.
Protalix BioTherapeutics Inc [PLX] stock has fluctuated between $0.99 and $3.10 over the past year. Protalix BioTherapeutics Inc [AMEX: PLX] shares were valued at $2.06 at the most recent close of the market.
Analyzing the PLX fundamentals
Protalix BioTherapeutics Inc [AMEX:PLX] reported sales of 61.95M for the trailing twelve months, which represents a growth of 16.21%. Gross Profit Margin for this corporation currently stands at 0.58% with Operating Profit Margin at 0.13%, Pretax Profit Margin comes in at 0.13%, and Net Profit Margin reading is 0.1%. To continue investigating profitability, this company’s Return on Assets is posted at 0.08, Equity is 0.15 and Total Capital is 0.15. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.11.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 2.0000 points at the first support level, and at 1.9400 for the second support level. However, for the 1st resistance point, the stock is sitting at 2.1000, and for the 2nd resistance point, it is at 2.1300.
Ratios To Look Out For
For context, Protalix BioTherapeutics Inc’s Current Ratio is 2.72. In addition, the Quick Ratio stands at 1.84 and the Cash Ratio stands at 0.74. Considering the valuation of this stock, the price to sales ratio is 2.65, the price to book ratio is 3.29 and price to earnings (TTM) ratio is 27.84.
Transactions by insiders
Recent insider trading involved Schwartz Aharon, Director, that happened on Jun 10 ’25 when 0.13 million shares were purchased.
